Compound ID | 1735
Class: Antibody (monoclonal antibody [mAb])
| Spectrum of activity: | Gram-positive |
| Details of activity: | Active against B. anthracis |
| Institute where first reported: | Human Genome Sciences (HGS) |
| Year first mentioned: | 2009 |
| Highest developmental phase: | Approved by FDA in 2012 |
| Development status: | Approved |
| External links: | |
| Guide to Pharmacology: | raxibacumab |
| Citations: |
|